SCHEMBL22636660

SCHEMBL22636660

Nc1cc(-c2cn[nH]c2)ccc1-c1ccccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 2/20 0.46
AKT2 P31751 2/20 0.45
AKT1 P31749 1/20 0.45
ROCK2 O75116 2/20 0.43
ALK Q9UM73 1/20 0.41
ROCK1 Q13464 1/20 0.41
TDO2 P48775 1/20 0.41
LRRK2 Q5S007 1/20 0.41
CHEK1 O14757 1/20 0.41
KCNH2 Q12809 1/20 0.40
GRM4 Q14833 1/20 0.40
PIM1 P11309 2/20 0.39
TGFBR1 P36897 2/20 0.39
MAPK14 Q16539 1/20 0.39
MAP3K5 Q99683 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALOX15 P16050 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ACVR1 Q04771 1/20 0.38
BTK Q06187 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29430735 1.00 FEN1 (0.46) FEN1AKT2AKT1ROCK2ALK
SCHEMBL29430626 0.82 AKT2 (0.59) FEN1AKT2AKT1ROCK2ALK
SCHEMBL22636741 0.82 AKT2 (0.59) FEN1AKT2AKT1ROCK2ALK
SCHEMBL29589848 0.78 AKT2 (0.61) AKT2AKT1CHEK1KCNH2GRM4
SCHEMBL1555341 0.78 AKT2 (0.61) AKT2AKT1CHEK1KCNH2GRM4
SCHEMBL22636756 0.78 MAPT (0.43) FEN1AKT2AKT1ALKTGFBR1
SCHEMBL22636821 0.77 MAPK1 (0.51) FEN1AKT2AKT1ROCK2ROCK1
SCHEMBL29430739 0.77 MAPK1 (0.51) FEN1AKT2AKT1ROCK2ROCK1
Hydrochloric Acid SCHEMBL30737454 0.76 AKT2 (0.59) AKT2AKT1CHEK1KCNH2GRM4
SCHEMBL21142257 0.75 FEN1 (0.47) FEN1AKT2AKT1ALKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2024-11-07 US disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-11-03 US disclosed
EP-3966196-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-03-16 EP disclosed
WO-2020225569-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2020-11-12 WO disclosed
WO-2020225569-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS CHP1, ERAP1, QSOX1 FEN1 4254/4885AKT2 2545/4885AKT1 2403/4885
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS ERAP1, CHP1, QSOX1 FEN1 4535/4885AKT2 2331/4885AKT1 2175/4885
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators ERAP1, CHP1, QSOX1 FEN1 4228/4885AKT2 2308/4885AKT1 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.